Andrea Ponti

RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR-edited stem cell-based therapy for a major disease to marketing authorization. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide. Discover more about our services at www.roslinct.com.

At FairJourney Bio, we specialize in cutting-edge antibody discovery and development, offering end-to-end solutions that fast-track your research. With over a decade of expertise, our innovative technologies and seasoned team have successfully advanced 19 antibodies to clinical stages. Our adaptable partnership model empowers projects of any scale, fostering collaboration and breakthrough innovation. Whether youre in early-stage research or development, we deliver tailored, high-quality antibodies designed to meet your specific needs. Join us in revolutionizing therapeutic discovery and making lasting impacts on global healthcare.

VISUfarma is a pan-European ophthalmic pharmaceutical company with a clear mission: to bring quality products and global therapeutic innovation to European eye health. We are an ambitious and fast growing ophthalmology company, commercializing a broad portfolio of pharmaceutical products and medical devices across Europe. (www.VISUfarma.com). The company was formed in 2016 and is the result of the successful combination of the Italian company Visufarma SpA and the commercial activities of the international Nicox SA, headquartered in France. The combination created VISUfarma. We offer a complete portfolio of products in the areas of : dry eye, eyelid hygiene, meibomian gland dysfunction (MGD), blepharitis & demodex management, retinal health, food supplements and glaucoma. Our growing portfolio of innovative products, and our commitment to ocular health, will bring new therapeutic solutions from around the world to help patients across Europe and in 20+ countries worldwide through exclusive distributors.

RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR-edited stem cell-based therapy for a major disease to marketing authorization. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide. Discover more about our services at www.roslinct.com.

Founded in Boston in 2007, ClearView Healthcare Partners is a diverse, inclusive, and innovative global strategy consulting firm serving the life science sector. The firm combines international industry knowledge and deep scientific expertise across a range of therapeutic areas with an extensive network of external stakeholders to deliver practical and actionable recommendations to our clients’ most complex challenges. The firm’s projects include cross-functional support at the corporate, franchise, and product levels for pharmaceutical, biotech, medical device, and diagnostics companies worldwide. We take pride in deploying high caliber consulting teams from our Boston, New York, San Francisco, London and Zurich offices that can provide the best support available on issues that require strategic capabilities and deep content expertise within life sciences. ClearView was ranked #13 overall and #1 boutique in the 2020 Vault Consulting 50. Specific rankings include Top 5 for Innovation, Formal and Informal Training, and Internal Mobility and Promotion Policies. ClearView was also ranked Top 10 for Firm Leadership, Compensation, and Firm Culture. CLEARVIEW HEALTHCARE PARTNERS® is a registered trademark of ClearView Healthcare Partners, LLC in the United States, the UK, Switzerland, the European Union, and various other countries. All Rights Reserved.

Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 19 of the top 20 pharmaceutical companies. We have earned the reputation of a best-in-class partner for medical affairs teams, with expertise in leading medical strategy, medical communications, publication planning & delivery, patient engagement, and more. And through our comprehensive suite of services and industry-leading technology solutions - including Two Labs, Okra.ai, Riparian, and 90TEN - we support clients across the product life cycle. Clients come to us for expertise in artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Our purpose-built software, scientific solutions, and behavior change expertise make us a unique partner to the pharmaceutical industry.

Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with 50+ years’ experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries. Sterling manages the most complex API and API intermediate challenges from proof-of-concept to commercial manufacture, as well as Antibody Drug Conjugate (ADC) development and manufacturing services. Sterling believes that while science can be complex, partnerships should be simple. That’s why they have redefined the CDMO experience, marked by transparency, collaboration and trust; a Partnership Development and Manufacturing Organisation (PDMO®). Sterling has six facilities across the UK, USA and Europe, employing 1,350+ people, including in Cramlington and Newcastle, UK; Deeside, Wales; Cork, Ireland, as well as North Carolina and Wisconsin in the US. Find out more: www.sterlingpharmasolutions.com/sterling-facilities

At FairJourney Bio, we specialize in cutting-edge antibody discovery and development, offering end-to-end solutions that fast-track your research. With over a decade of expertise, our innovative technologies and seasoned team have successfully advanced 19 antibodies to clinical stages. Our adaptable partnership model empowers projects of any scale, fostering collaboration and breakthrough innovation. Whether youre in early-stage research or development, we deliver tailored, high-quality antibodies designed to meet your specific needs. Join us in revolutionizing therapeutic discovery and making lasting impacts on global healthcare.